A Study to Evaluate the Effects of a Prebiotic Soda on Glycemic Control in Adults

NCT ID: NCT07298135

Last Updated: 2025-12-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

224 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-31

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this study is to evaluate the chronic effects of replacing traditional non-diet soda with a prebiotic soda on biomarkers associated with glycemic control in adults with glucose dysregulation who are habitual consumers of traditional soda.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary aim of this clinical trial is to evaluate the effects of replacing traditional non-diet soda with a prebiotic soda (i.e., OLIPOP) over an 8 week period on markers of glucose (blood sugar) control in adults with glucose (blood sugar) dysregulation.

Participants (n=224) will be habitual consumers of traditional non-diet sodas, consuming on average 2-3 servings of non-diet soda daily. Participants will be randomized to either an active control group (continued habitual traditional non-diet soda intake, 2 - 3 servings/day) or a behavioral intervention group (OLIPOP prebiotic soda, 2 cans/day, 6 g dietary fiber and 2 - 5 g total sugar per can).

Secondary outcomes will include evaluating the effects of prebiotic soda consumption on additional markers of metabolic health, including long-term glycemic control and insulin sensitivity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blood Glucose Control

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, Open-Label, Controlled
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Participants will be randomized to replace traditional non-diet soda with prebiotic soda

Group Type EXPERIMENTAL

Prebiotic Soda

Intervention Type BEHAVIORAL

Participants will replace traditional non-diet sodas in their diet with a prebiotic soda (OLIPOP). Participants will consume 2 cans/day (24 fl. oz/day) that will add 12 g dietary fiber/day to their diet.

Control Group

Participants will be randomized to continue consumption of traditional non-diet soda.

Group Type ACTIVE_COMPARATOR

Active Control

Intervention Type BEHAVIORAL

Participants will continue to consume their habitual intake (on average 2-3 servings/day) of traditional non-diet soda.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prebiotic Soda

Participants will replace traditional non-diet sodas in their diet with a prebiotic soda (OLIPOP). Participants will consume 2 cans/day (24 fl. oz/day) that will add 12 g dietary fiber/day to their diet.

Intervention Type BEHAVIORAL

Active Control

Participants will continue to consume their habitual intake (on average 2-3 servings/day) of traditional non-diet soda.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to provide informed consent
* Willing to comply with all study procedures
* Ages 40 - 70 years old
* Habitual consumers of traditional non-diet soda (average intake 2 - 3 servings/daily)
* BMI between 25 - 35 kg/m²
* Waist-to-Hip ratio ≥0.85 for Women and ≥0.9 for Men
* Fasting plasma glucose between 100 - 125 mg/dL
* Consumes ≤16 g total fiber per day to align with the current average dietary fiber intake of American adults
* Non-user or former user (cessation ≥ 12 months) of tobacco or nicotine products
* Non-user of marijuana and hemp products, including CBD products, in the previous 60 days
* Willing to maintain habitual diet (with the exception of study products) and physical activity patterns throughout the trial

Exclusion Criteria

* Inability to consume a standard 12 fl. oz. carbonated beverage twice daily
* Currently engaged or planning to be on an intensive weight loss regimen program
* Extreme dietary habits or has been diagnosed with an eating disorder
* Habitual use of fiber supplements, inulin-based supplements, acacia fiber, glucomannan, prebiotic supplements, or probiotic supplements within the previous 30 days
* Known allergy or sensitivity to any of the ingredients in the study products
* History or presence of uncontrolled and/or clinically important medical conditions that could interfere with study results interpretation (ex. uncontrolled diabetes mellitus, CKD stage 4-5, severe liver disease/cirrhosis, uncontrolled hypertension, recent myocardial infarction or stroke (within 6 months), severe mental illness or cognitive impairment, immunodeficiency disorders, active infections).
* Gastrointestinal conditions that could potentially interfere with absorption of the study product
* Use of oral or injectable steroids in the previous 90 days
* Use of antibiotic therapy in the previous 90 days
* Unstable use of prescription medications within the previous 90 days that affect plasma glucose levels
* History or presence of cancer, except non-melanoma skin cancer, in the previous 2 years
* Exposure to any non-registered drug product or participation in another intervention study in the previous 30 days
* Recent history (within 12 months) of alcohol or substance abuse
* History of major trauma or surgical event in the previous 60 days
* Person who is pregnant, planning pregnancy, lactating, or unwilling to use contraception during the study period
* Any condition the Investigator believes would interfere with study participation or compliance
* Consumption of pre-biotic sodas in the previous 30 days
Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Olipop, PBC

INDUSTRY

Sponsor Role lead

Lindus Health

INDUSTRY

Sponsor Role collaborator

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Courtney McCormick, MPH, RDN, LDN

Role: CONTACT

Phone: 18145719644

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20254308

Identifier Type: -

Identifier Source: org_study_id